A newly published case report in the renowned Journal of Neuro-Oncology Discovery provides compelling clinical evidence of the feasibility, safety and workflow integration of the Pentalafen®/Heliance® combination therapy in treating glioblastoma. This case, drawn from the Hemerion-sponsored Phase 1/2 clinical trial at the University of Pittsburgh Medical Center, highlights the potential of Hemerion’s technology to fundamentally transform the landscape of cancer treatment, especially for central nervous system diseases.
Glioblastoma’s main therapeutic hurdle lies in its invasive character. Despite seemingly successful surgical removal, residual tumor cells inevitably persist in the adjacent brain tissue, causing the tumor to return.
The detailed integration of Hemerion’s technology for tackling residual glioblastoma tumor cells intraoperatively is highlighted in a new peer-reviewed case report.
This publication, titled “Intraoperative photodynamic therapy in glioblastoma: a case report and review of the literature” provides a deeper look into the approach.
The Hemerion drug-device therapy associates a photosensitizer (Pentalafen® ) and an innovative illumination platform to perform photodynamic treatment intraoperatively after a glioblastoma resection.
In this specific case, Pentalafen® was administered four hours before the resection. This photosensitizer is designed to accumulate in cancer cells while being eliminated by healthy cells. It was then light-activated to achieve two complementary goals:
- Fluorescence-Guided Surgery: A specific wavelength is used during the tumor resection to guide the surgery by fluorescence.
- Targeted Cancer Cell Destruction: After the tumor is removed, the Heliance illumination platform is deployed to activate a reaction in the residual cancerous cells, leading to their destruction.
The Case: Key Clinical Outcomes
This publication highlights several critical advantages of the Hemerion drug-device therapy in the treatment of glioblastoma:
Potential efficacy: At 3-month follow-up, the patient remained neurologically stable with no evidence of tumor recurrence.
Seamless integration: The Heliance® platform was seamlessly integrated into the standard surgical procedure, proving its clinical utility in a high-stakes operating room environment. The patient then initiated adjuvant chemoradiotherapy (Stupp protocol), Hemerion’s combination therapy fits seamlessly into standard care.
Proven Safety: The procedure confirmed the excellent safety profile observed in previous Phase 1 / 2 trials, with no adverse neurological side effects reported.
A strong foundation for the upcoming pivotal phase 3 trial
Hemerion’s focus is now firmly set on the final clinical steps toward market authorization, building on significant progress. This includes securing a recent FDA Fast Track designation, the green light for the Accelerated Approval procedure, and promising survival data. Earlier trials, for example, demonstrated a progression-free survival (PFS) of 17.1 months, substantially surpassing the 7-month standard of care.
This peer-reviewed publication reinforces the scientific maturity of Hemerion’s technology. It comes at a decisive time as our company prepares for its next multicentric pivotal study. It also confirms to the investment community that our combined therapy is ready for large-scale clinical implementation.